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A206 Abstracts
in Medline, EMBASE, International Pharmacological Abstracts and the Cochrane 
Collaboration. Two independent reviewers identiﬁed the abstracts, selected the full 
articles, and extracted the data. Odds ratios and weighted means differences were 
calculated. Random effects models were employed in the analyses with RevMan v.5.0 
software. RESULTS: A total of 1253 studies were reviewed and 10 trials were ﬁnally 
selected where parecoxib was assessed in hip, knee and spine surgeries, as well as 
bunionectomy. In 6/10 studies, parecoxib 40 mg showed a higher global treatment 
evaluation against placebo (OR 0.20; 95%CI 0.13–0.31) and improvements in the 
consuming rescue drugs rate (OR 0.18; 95%CI 0.07–0.47), as well as in cumulative 
morphine consumption, and pain intensity (p < 0.001). In three studies, parecoxib 
was as effective as ketorolac, paracetamol, metamizole or morphine. Frequency of AE 
was similar between parecoxib and placebo or other drugs. Parecoxib 20 mg showed 
less postoperative fever than placebo (OR 0.46; 95%CI 0.24–0.89). CONCLUSIONS: 
Parecoxib 40 mg is an effective and safe analgesic option during the ﬁrst hours of the 
postoperative period in orthopedic surgeries.
SYSTEMIC DISORDERS/CONDITIONS – Cost Studies
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OBJECTIVES: The purpose of this study was to model the economic impact of a prior 
authorization (PA) requirement for pregabalin from a US health plan perspective. 
METHODS: An Excel-based model was developed to simulate two hypothetical 
scenarios: 1) A health plan in which a PA is placed on pregabalin, and 2) a health 
plan in which there is no PA. In both scenarios, a mix of brand and generic products 
based on secondary prescription data from IMS was assumed dispensed to patients 
who did not receive a pregabalin prescription or who were denied pregabalin in the 
PA process. PA rejection rates were obtained from a PBM database analysis. The 
pregabalin prescribing rate was set to 10.3% in both the PA and no PA scenarios, 
with a denial rate of 50% in the PA scenario. The model incorporated the drug 
wholesale acquisition cost (WAC) or the federal upper limit for generics, cost of PA 
administration (published literature), and copayments, in each scenario for a cohort 
of 1000 patients over a one-year period. Sensitivity analyses were carried out 
with various PA administration costs and product mixes for the pregabalin alternatives. 
RESULTS: The difference in costs between the two scenarios was 0.4% ($886,000 
for the PA scenario vs. $889,000 for the “no PA” scenario). Setting the PA administra-
tion cost to zero, the difference in drug acquisition costs alone was 0.8%. When the 
product alternatives to pregabalin were replaced with gabapentin only, the difference 
in drug acquisition costs alone was 3.4%. CONCLUSIONS: Based on the actual mix 
of products used across pregabalin indications, a PA on pregabalin has a minimal 
impact on total costs to the health plan. The difference in drug acquisition costs was 
less than 1% for a mix of product alternatives based on audited prescription data.
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OBJECTIVES: Compare direct health care resource utilization and costs of post 
herpetic neuralgia (PHN) patients initiating lidocaine or gabapentin/pregabalin. 
METHODS: Patients with PHN diagnosis (ICD-9-CM: 053.12, 053.13 or 053.19) or 
herpes zoster diagnosis (ICD-9-CM: 053.0x, 053.10, 053.11, 053.2x, 053.7x-053.9x) 
and at least 30 days PHN-related treatment were identiﬁed from Medicaid claims data 
from Florida, Iowa, Missouri, and New Jersey, 1999–2007. Patients initiated mono-
therapy with lidocaine or gabapentin/pregabalin after PHN diagnosis, had continuous 
eligibility 6 months before (baseline) and 6 months after (study period) the medication 
index date, and were at least 18 years old. Lidocaine patients were matched to patients 
initiating gabapentin/pregabalin on age and propensity to initiate lidocaine based on 
baseline characteristics. Study period direct resource use and costs, calculated as 
reimbursements to providers for medical services and prescription drugs, were com-
pared between the two matched groups using univariate analysis. RESULTS: After 
matching on age and propensity to initiate lidocaine, baseline characteristics (such as 
age, comorbidities, prior resource use and direct costs) were well-balanced between 
the treatment groups. Matched patients were on average 61 years old, 73% were 
women, approximately 24% had a mental disorder diagnosis, and 55% had other 
painful conditions during the baseline period. Among matched lidocaine (n = 306) 
and gabapentin/pregabalin (n = 306) patients, there were no statistically signiﬁcant 
differences in study period treatment with tricyclic antidepressants (16.0% in both 
groups), analgesic medications (86.6% vs. 86.9%), and other PHN-related treatments 
(6.9% vs. 6.2%) such as DREZ lesions, epidural steroids and nerve blocks. No statisti-
cally signiﬁcant differences were found in resource use, average total health care costs 
per patient ($8,740 vs. $8,630, P = 0.880) and PHN-related costs ($1,046 vs. $1,067, 
P = 0.908) between matched lidocaine and gabapentin/pregabalin patients. CONCLU-
SIONS: PHN patients treated with lidocaine cost no more than patients treated with 
gabapentin or pregabalin over the 6-month study period.
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OBJECTIVES: To assess maintenance treatment patterns of inﬂiximab (IFX) in ulcer-
ative colitis (UC) and the impact of persistence on UC-related hospitalization. 
METHODS: A retrospective claims analysis using the IMS LifeLinkTM Health Plan 
Claims Database between September 1, 2004 and March 31, 2009 was conducted. 
The index date was deﬁned as the ﬁrst claim for IFX between September 1, 2005 and 
January 1, 2008. Continuous enrollment for 12 months prior and 14 months after 
the index date was required. Patients were required to have ≥2 claims with an ICD-9 
diagnosis code for UC pre-index and be ≥18 years at index. Patients with selected 
other inﬂammatory diseases and those undergoing colectomy within 12 weeks of the 
index date were excluded. Patients with ≥1 infusion following day 56 post index were 
considered to have maintenance therapy. Hospitalizations were compared to the group 
of patients with induction infusions only. Within the maintenance treatment group, 
therapeutic persistence was deﬁned as a medication possession ratio (MPR) of ≥80%; 
this group was compared to those without therapeutic persistence (<80% MPR). 
RESULTS: A total of 420 patients were included in the analyses; mean (SD) age = 
43.9 (14.1) years; 47.9% female; mean (SD) 6.08 (2.49) IFX infusions; 84.3% (n = 
354) continued to maintenance therapy. Maintenance patients incurred fewer UC-
related hospitalizations (0.12 vs. 0.32), associated costs ($3118 vs. $8610) and had 
shorter average lengths of stay (ALOS; 8.9 vs. 11.65 days) than induction-only 
patients. Among maintenance patients, those demonstrating therapeutic persistence (n 
= 202; 57.1%) incurred fewer UC-related hospitalizations (0.03 vs. 0.22) and associ-
ated costs ($423 vs. $6678), and had shorter ALOS (6.67 vs. 9.71 days) than those 
without therapeutic persistence. CONCLUSIONS: Persistent maintenance treatment 
with IFX is associated with fewer UC-related hospitalizations, lower inpatient costs, 
and shorter ALOS among patients with UC. Physicians should monitor patients with 
UC to ensure appropriate IFX maintenance therapy paradigms are followed.
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OBJECTIVES: To quantify individual and national estimates of the direct costs of 
inﬂammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), 
using national survey data. METHODS: This was a retrospective study using 1996–
2006 data from the Medical Expenditure Panel Survey (MEPS). Individuals self-
reported health conditions were mapped to the International Classiﬁcation of Diseases, 
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic codes. Individuals with an 
ICD-9-CM diagnostic code of 555.x (CD) or 556.x (UC) were categorized as having 
IBD. Health care services included prescriptions, inpatient, outpatient, emergency 
room, ofﬁce, and home health services. Health care costs were collected for the health 
care services. Out-of-pocket (OOP) costs were the portion of individuals’ total pay-
ments for the health care services. To estimate the health care and OOP costs, an 
ordinary least squares model was performed. Individuals with and without IBD were 
compared. RESULTS: There were 411 individuals with IBD (mean age = 47.7 years; 
57% Female), and 161,953 individuals without IBD (mean age = 48.2 years; 58% 
Female). The annual per capita health care costs for individuals with IBD were more 
than double those for individuals without IBD ($11,759 vs. $5,700; p < 0.001). The 
annual per capita OOP costs for individuals with IBD were also almost twice those 
of individuals without IBD ($2,082 vs. $1,147; p < 0.001). When combining health 
care and OOP costs, IBD increases the total annual per capita direct costs by $7,021. 
The US national annual estimates of the health care, OOP, and total direct costs 
secondary to IBD are $2.8 billion, $0.4 billion, and $3.2 billion respectively. CON-
CLUSIONS: The direct costs associated with IBD are substantial not only to health 
care payers but to patients as well. The extent to which appropriate and early diagnosis 
and treatment of IBD reduce the total health care costs for individuals with this disease 
should be examined.
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OBJECTIVES: To quantify individual and national estimates of the direct medical 
costs of psoriasis (PsO) and similar disorders, using national survey data. METHODS: 
This was a retrospective study using 1996–2006 data from the Medical Expenditure 
Panel Survey (MEPS). Individuals’ self-reported current health conditions were 
mapped to International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation 
(ICD-9-CM) diagnostic codes. Individuals with an ICD-9-CM diagnostic code of 696.
xx were categorized as having PsO. Health care services included prescriptions, inpa-
tient, outpatient, emergency room, ofﬁce, and home health services. Health care costs 
